Association of E-cadherin and β-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas

Human Pathology

Volumn 35, Issue 6, 2004, Pages 663-669

  Faleiro Rodrigues, Cristina ^a,b   Macedo Pinto, Isabel ^a   Pereira, Deolinda ^a   Ferreira, Veronica M ^a   Lopes, Carlos S ^a  

^a Administracao Regional de Saude do Norte   (Portugal)

^b PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

Author keywords

catenin; cell adhesion molecules; E cadherin; epithelial cadherin; FIGO; International Federation of Gynaecology and Obstetrics; ovarian carcinomas

Indexed keywords

BETA CATENIN; UVOMORULIN; CADHERIN; CTNNB1 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; TRANSACTIVATOR PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SIZE; CANCER STAGING; CLEAR CELL CARCINOMA; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PERITONEUM METASTASIS; PHENOTYPE; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; ADENOCARCINOMA; BIOSYNTHESIS; COMPARATIVE STUDY; METABOLISM; METASTASIS; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; PROGNOSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; CADHERINS; CYTOSKELETAL PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 3042734821     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2004.01.024     Document Type: Article

References (45)

1. Barns M.N., Grizzle W.E., Grubbs C.J., Patridge E.E. Paradigms for primary prevention of ovarian carcinoma. CA Cancer J Clin. 52:2002;216-225
2. Fox H., Wells M. Histopathology of epithelial ovarian cancer with particular reference to prognostic factors. CME J Gynecol Oncol. 4:1999;142-150
3. Friedlander M.L. Prognostic factors in ovarian cancer. Semin Oncol. 25:1998;305-314
4. Frixen U.H., Behrens J., Sachs M., et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol. 113:1991;173-185
5. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science. 251:1991;1451-1455
6. Birchmeier W., Behrens J. Cadherin expression in carcinomas Role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta. 1198:1994;11-26
7. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol. 153:1998;333-339
8. Shiozaki H., Oka H., Inoue M., et al. E-cadherin mediated adhesion system in cancer cells. Cancer. 77:1996;1605-1613
9. Hinck L., Näthke I.S., Papkoff J., et al. Dynamics of cadherin/catenin complex formation Novel protein interactions and pathways of complex assembly. J Cell Biol. 125:1994;1327-1340
10. Kemler R. From cadherins to catenins Cytoplasmatic protein interactions and regulation of cell adhesion. Trends Genet. 9:1993;317-321
11. Nagafuchi A., Takeichi M. Cell binding function of E-Cadherin is regulated by the cytoplasmic domain. EMBO J. 7:1988;3679-3684
12. Handschuh G., Candidus S., Luber B., et al. Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene. 18:1999;4301-4312
13. Oyama T., Kanai Y., Ochiai A., et al. A truncated β-catenin disrupts the interaction between E-Cadherin and α-catenin A cause of loss of intercellular adhesiveness in human cancer cell lines. Cancer Res. 54:1994;6282-6287
14. Shimoyama Y., Nagafuchi A., Fujita S., et al. Cadherin dysfunction in a human cancer cell line Possible involvement of loss of α-catenin expression in reduced cell-cell adhesiveness. Cancer Res. 52:1992;5770-5774
15. Bànkfalvi À, Krabort M., Buchwalow I.B., et al. Gains and losses of adhesion molecules (CD44, E-cadherin, β-catenin) during oral carcinogenesis and tumour progression. J Pathol. 198:2002;343-351
16. Huiping C., Kristjansdottir S., Jonasson J.G., et al. Alterations of E-cadherin and β-catenin in gastric cancer. BMC Cancer. 1:2001;16-25
17. Krishnadath K.K., Tilanus H.W., van Blankenstein M., et al. Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J Pathol. 182:1997;331-338
18. Shimazui T., Schalken J.A., Giroldi L.A., et al. Prognostic value of cadherin-associated molecules (α-, β-, γ-catenins and p120cas) in bladder tumors. Cancer Res. 56:1996;4154-4158
19. Shinichiro K., Sugio K., Yamazaki K., et al. Expression of E-cadherin and β-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res. 6:2000;4789-4796
20. Yoshida R., Kimura N., Harada Y., et al. The loss of E-cadherin, α and β-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer. Int J Oncol. 18:2001;513-520
21. Bullions L.C., Notterman D.A., Chung L.S., et al. Expression of wild-type α-catenin protein in cells with a mutant α-catenin gene restores both growth regulation and tumour suppressor activities. Mol Cell Biol. 17:1997;4501-4508
22. Vandenbossche G.M.R., de Bruyne G.K., Bruyneel E.A., et al. Micro-encapsulation of MDCK-ras -e cells prevents loss of E-cadherin invasion-suppressor function in vivo. Int J Cancer. 57:1994;73-80
23. Vleiminckx K., Vakaet I. Jr, Mareel M., et al. Genetic manipulation of E-cadherin expression by epithelial tumour cells reveals an invasion suppressor role. Cell. 66:1991;107-119
24. Winn R.A., Bremnes R.M., Bemis L., et al. Gamma-catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. Oncogene. 21:2002;7497-7506
25. Scully R.E. Based on (with some modification) the classification of World Health Organization, 2nd ed. Histological typing of ovarian tumours. WHO International histological classification of tumours. 1999;Springer-Verlag, Berlin
26. De Benedet J.L., Bender H., Jones H. 3rd, et al. FIGO staging classifications and clinical guidelines in the management of gynecologic cancers, FIGO Committee on Gynecologic Oncology. Int J Gynecol Obstet. 70:2000;209-262
27. Bracke M.E., Van Roy F.M., Mareel M.M. The E-cadherin/catenin complex in invasion and metastases. Curr Top Microbiol Immunol. 213:1996;124-161
28. Jawhari A., Jordan S., Poole S., et al. Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma Relationship with patient survival. Gastroenterology. 112:1997;46-54
29. Vermeulen S.J., Bruyneel E.A., Bracke M.E., et al. Transition from the noninvasive to the invasive phenotype and loss of α-catenin in human colon cancer cells. Cancer Res. 55:1995;4722-4728
30. Bànkfalvi À, Terpe H.J., Breukelmann D., et al. Immunophenotypic and prognostic analysis of E-cadherin and β-catenin expression during breast carcinogenesis and tumour progression A comparative study with CD44. Histopathology. 34:1999;25-34
31. Bukholm I.K., Nesland J.M., Karesen R., et al. E-cadherin and α-, β-, and γ-catenin protein expression in relation to metastasis in human breast carcinoma. J Pathol. 185:1998;262-266
32. De Leeuw W.J.F., Berx G., Vos C.B., et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol. 183:1997;404-411
33. Chow V., Yuen P.W.A., Lam K.Y., et al. A comparative study of the clinicopathological significance of E-cadherin and catenins (α-, β- and γ-) expression in the surgical management of oral tongue carcinoma. J Cancer Res Clin Oncol. 127:2001;59-63
34. Endo K., Eda T., Ueyama J., et al. Immunoreactive E-cadherin, alpha-catenin, beta-catenin and gamma-catenin proteins in hepatocellular carcinoma Relationships with tumour grade, clinicopathological parameters, and patients survival. Hum Pathol. 31:2000;558-565
35. Böhm J., Niiskanen L., Kiraly K. Expression and prognostic factor of α, β- and γ-catenin in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 85:2000;4806-4811
36. Darai E., Scoazec J.-Y., Walker-Combrouze F., et al. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors. Hum Pathol. 28:1997;922-928
37. Davies B.R., Worsley S.D., Ponder B.A.J. Expression of E-cadherin, α- and β-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopathology. 32:1998;69-80
38. Fujioka T., Takebayashi Y., Kihana T., et al. Expression of E-cadherin and β-catenin in primary and peritoneal metastatic ovarian carcinoma. Oncol Rep. 8:2001;249-255
39. Hoffman A.G., Burghardt R., Tilley R., et al. An in vitro model of ovarian epithelial carcinogenesis Changes in cell-cell communication and adhesion occurring during neoplastic progression. Int J Cancer. 54:1993;828-838
40. Inoue M., Ogawa H., Miyata M., et al. Expression of E-cadherin in normal, benign, and malignant tissues of female genital organs. Am J Clin Pathol. 98:1992;76-80
41. Auersperg N., Edelson M.I., Mok S.C., et al. The biology of ovarian cancer. Semin Oncol. 25:1998;281-304
42. Barker N., Clevers H. Catenins, Wnt signaling and cancer. Bioessays. 22:2000;961-965
43. Resnik E. β-catenin - one player, two games. Nat Genet. 16:1997;9-11
44. Willert K., Nusse R. β-catenin A key mediator of Wnt signaling. Curr Opin Genet Dev. 8:1998;95-102
45. Morin P.J. β-catenin signaling and cancer. BioEssays. 21:1999;1021-1030